2 completed, 1 active not recruiting. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Active not recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow cenerimod: new trials by email Literature Review of cenerimod trials Research Report on cenerimod
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety,Tolerability,Pharmacokinetics and Pharmacodynamics of Cenerimod in Adult Chinese Participants With Moderate-to-severe Systemic Lupus Erythematosus (SLE) cenerimod 4 mg - SLE - Systemic Lupus Erythematosus | Phase 2 | Active not recruiting | Viatris Pharmaceuticals Co., Ltd. | 15 | 2026-01-14 | 2026-07-28 |
| Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus Cenerimod 0.5 mg, Cenerimod 1 mg, Cenerimod 2 mg - Systemic Lupus Erythematosus | Phase 2 | Completed | Viatris Innovation GmbH | 427 | 2018-12-21 | 2026-07-29 |
| Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus Matching placebo, Cenerimod - Systemic Lupus Erythematosus | Phase 1 / Phase 2 | Completed | Viatris Innovation GmbH | 105 | 2015-06-01 | 2026-07-29 |
Lupus Erythematosus, Systemic (3) · Connective Tissue Diseases (1)
Viatris Innovation GmbH (2) · Viatris Pharmaceuticals Co., Ltd. (1)
Bulgaria (2) · Georgia (2) · Russia (2) · Ukraine (2) · United States (2) · Belarus (1) · Chile (1) · China (1) · Czechia (1) · France (1) · Germany (1) · Greece (1) · Hungary (1) · Israel (1) · Italy (1)
PMID 31798918, PMID 39586304, PMID 39919901
2018 (1)